We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Renal Cell Carcinoma

Journal Scan / Research · July 10, 2019

High Response Rate With Gemcitabine + Axitinib in RCC With a Predominant Sarcomatoid Component

Investigational New Drugs


Additional Info

Disclosure statements are available on the authors' profiles:

Investigational New Drugs
A Multicenter, Prospective Phase II Trial of Gemcitabine Plus Axitinib in Patients With Renal Cell Carcinoma With a Predominant Sarcomatoid Component
Invest New Drugs 2019 Jun 24;[EPub Ahead of Print], I Park, HJ Lee, WK Bae, S Yoon, JL Lee

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading